Can't connect right now! retry

health
Thursday Feb 15 2018
By
REUTERS

FDA approves J&J prostate cancer treatment

By
REUTERS
A Johnson & Johnson building is shown in Irvine, California, US, January, 24, 2017. REUTERS/Mike Blake/Files

The US Food and Drug Administration (FDA) on Wednesday approved Johnson & Johnson’s Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

The drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the FDA said in a statement.

Comments

Notification Management


Pakistan
World
Entertainment
Lifestyle
Sports
Business
Videos
Tv Shows
Health

Subscribe to desktop notification
Powered by IMM